Myocardial ischemia is a medical condition characterized by reduced blood flow to the heart muscle, leading to inadequate oxygen supply. This can result in damage to the heart muscle and, if left untreated, can lead to more severe complications, such as a heart attack.
Novartis' pelacarsen shows positive Phase 3 results in reducing recurrent events after myocardial infarction (MI): This novel investigational drug demonstrated potential in preventing subsequent heart attacks or hospitalizations for heart failure after an initial MI.
Recardio's dutoglituplin reaches Phase 3 trial stage for stable angina: This glucagon-like peptide-1 receptor agonist aims to improve symptoms and quality of life in patients with chronic stable angina, a form of myocardial ischemia.
Boehringer Ingelheim collaborates with Eli Lilly and Company on Jardiance for cardiovascular outcomes: This partnership expands the potential use of Jardiance, an SGLT2 inhibitor, for preventing major adverse cardiovascular events in patients with established cardiac risk factors, including myocardial ischemia.
Medtronic acquires Fortive Corporation's Cardiovascular and Surgical Technologies business: This deal strengthens Medtronic's cardiac rhythm management and structural heart solutions portfolio, with a focus on minimally invasive therapies for angina and other ischemic conditions.
Myocardial Ischemia Market Highlights:
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)